ATE514416T1 - Argatrobanformulierung mit einer säure als lösungsvermittler - Google Patents

Argatrobanformulierung mit einer säure als lösungsvermittler

Info

Publication number
ATE514416T1
ATE514416T1 AT06802424T AT06802424T ATE514416T1 AT E514416 T1 ATE514416 T1 AT E514416T1 AT 06802424 T AT06802424 T AT 06802424T AT 06802424 T AT06802424 T AT 06802424T AT E514416 T1 ATE514416 T1 AT E514416T1
Authority
AT
Austria
Prior art keywords
acid
solvent
argatroban
formulation
argatroban formulation
Prior art date
Application number
AT06802424T
Other languages
English (en)
Inventor
George Owoo
Richard A Burgos
Original Assignee
Baxter Internat Inc A Delaware Corp
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Internat Inc A Delaware Corp, Baxter Healthcare Sa filed Critical Baxter Internat Inc A Delaware Corp
Application granted granted Critical
Publication of ATE514416T1 publication Critical patent/ATE514416T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
AT06802424T 2005-09-01 2006-08-28 Argatrobanformulierung mit einer säure als lösungsvermittler ATE514416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71340305P 2005-09-01 2005-09-01
PCT/US2006/033432 WO2007027565A2 (en) 2005-09-01 2006-08-28 Argatroban formulation comprising an acid as solubilizer

Publications (1)

Publication Number Publication Date
ATE514416T1 true ATE514416T1 (de) 2011-07-15

Family

ID=37809398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06802424T ATE514416T1 (de) 2005-09-01 2006-08-28 Argatrobanformulierung mit einer säure als lösungsvermittler

Country Status (23)

Country Link
US (3) US7642271B2 (de)
EP (1) EP1948133B1 (de)
JP (1) JP5189980B2 (de)
KR (3) KR20150108430A (de)
CN (2) CN101257890B (de)
AT (1) ATE514416T1 (de)
AU (1) AU2006285097B2 (de)
BR (1) BRPI0616127B8 (de)
CA (1) CA2617920C (de)
CY (1) CY1112109T1 (de)
DK (1) DK1948133T3 (de)
ES (1) ES2368758T3 (de)
HK (2) HK1123193A1 (de)
IL (2) IL189290A (de)
IN (1) IN2015DN03947A (de)
MX (1) MX2008002177A (de)
NZ (1) NZ565821A (de)
PL (1) PL1948133T3 (de)
PT (1) PT1948133E (de)
RU (1) RU2416393C2 (de)
SI (1) SI1948133T1 (de)
WO (1) WO2007027565A2 (de)
ZA (1) ZA200802667B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150108430A (ko) * 2005-09-01 2015-09-25 백스터 인터내셔널 인코포레이티드 가용화제로서의 산을 포함하는 아가트로반 제제
US7589106B2 (en) 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20090221637A1 (en) * 2008-02-29 2009-09-03 Baxter International Inc. Solid-state salt argatroban formulations and methods for producing and using the same
US7915290B2 (en) 2008-02-29 2011-03-29 Baxter International Inc. Argatroban formulations and methods for making and using same
CN101598725B (zh) * 2009-06-23 2012-07-18 南通大学附属医院 阿加曲班在血细胞和生化常规分析中的应用
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
CN102120026A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以醇作为增溶剂的21(s)阿加曲班静脉注射液
CN102228677A (zh) * 2011-06-17 2011-11-02 天津市炜杰科技有限公司 以酸作为增溶剂的21(r)阿加曲班静脉注射液
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
EP3383494A4 (de) * 2015-12-04 2019-08-07 The Regents of The University of California Histondeacetylase-inhibitoren
CN107773533A (zh) * 2016-08-26 2018-03-09 四川科瑞德制药股份有限公司 一种新型凝血酶抑制剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420919B (sv) * 1973-08-13 1981-11-09 Mitsubishi Chem Ind Forfarande for framstellning av n?722-dansyl-l-argininderivat och farmaceutiskt godtagbara syradditionssalter derav
US5214052A (en) * 1987-07-28 1993-05-25 Mitsubishi Kasei Corporation Method for dissolving arginineamides and pharmaceutical compositions containing them
CA2091715A1 (en) 1992-03-18 1993-09-19 Mitsubishi Kasei Corporation Argatroban preparations for ophthalmic use
US5506241A (en) * 1992-03-18 1996-04-09 Mitsubishi Chemical Corporation Argatroban preparations for ophthalmic use
JPH06219949A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
JPH06219948A (ja) * 1993-01-25 1994-08-09 Mitsubishi Kasei Corp 抗トロンビン剤及びその製造方法
DE69417087T2 (de) 1993-04-22 1999-07-15 Senju Pharma Co Wässrige Arzneizubereitungen enthaltend Argatroban und Cyclodextrin oder Coffein
JPH07228532A (ja) * 1993-04-22 1995-08-29 Senju Pharmaceut Co Ltd 水性液剤、その有効成分の溶解性向上方法および安定化方法
US5849843A (en) * 1993-11-16 1998-12-15 Baxter International Inc. Polymeric compositions for medical packaging and devices
US5998019A (en) * 1993-11-16 1999-12-07 Baxter International Inc. Multi-layered polymer structure for medical products
FR2715566B1 (fr) * 1994-02-03 1996-03-08 Synthelabo Solutions aqueuses concentrées d'argatroban.
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
JPH10316569A (ja) * 1997-05-19 1998-12-02 Mitsubishi Chem Corp アルガトロバンの可溶化方法及びそれによるアルガトロバン含有外用水性薬剤
TW200505422A (en) * 2003-03-20 2005-02-16 Mitsubishi Pharma Corp Pharmaceutical preparations containing arginine amides
WO2005009361A2 (en) 2003-07-17 2005-02-03 Smithkline Beecham Corporation Method of treating hit patients with argatroban
KR20150108430A (ko) * 2005-09-01 2015-09-25 백스터 인터내셔널 인코포레이티드 가용화제로서의 산을 포함하는 아가트로반 제제

Also Published As

Publication number Publication date
RU2008112311A (ru) 2009-10-10
WO2007027565A2 (en) 2007-03-08
EP1948133B1 (de) 2011-06-29
IN2015DN03947A (de) 2015-10-02
HK1178053A1 (en) 2013-09-06
US7642271B2 (en) 2010-01-05
NZ565821A (en) 2010-05-28
CN101257890A (zh) 2008-09-03
US20100099706A1 (en) 2010-04-22
CN102895179B (zh) 2014-10-22
HK1123193A1 (en) 2009-06-12
ES2368758T3 (es) 2011-11-22
IL189290A (en) 2011-10-31
US7985757B2 (en) 2011-07-26
SI1948133T1 (sl) 2011-08-31
CN101257890B (zh) 2012-10-31
BRPI0616127B1 (pt) 2020-05-12
CN102895179A (zh) 2013-01-30
RU2416393C2 (ru) 2011-04-20
US20100099705A1 (en) 2010-04-22
JP2009507018A (ja) 2009-02-19
CY1112109T1 (el) 2015-11-04
US8034830B2 (en) 2011-10-11
BRPI0616127A2 (pt) 2011-06-07
EP1948133A2 (de) 2008-07-30
DK1948133T3 (da) 2011-10-03
KR20140009599A (ko) 2014-01-22
PL1948133T3 (pl) 2012-03-30
PT1948133E (pt) 2011-08-01
WO2007027565A3 (en) 2007-10-04
US20070049617A1 (en) 2007-03-01
IL189290A0 (en) 2008-06-05
AU2006285097A1 (en) 2007-03-08
KR20150108430A (ko) 2015-09-25
ZA200802667B (en) 2009-01-28
MX2008002177A (es) 2008-04-22
KR101753949B1 (ko) 2017-07-04
JP5189980B2 (ja) 2013-04-24
BRPI0616127B8 (pt) 2021-05-25
CA2617920C (en) 2014-05-27
IL208183A0 (en) 2010-12-30
CA2617920A1 (en) 2007-03-08
KR20080042155A (ko) 2008-05-14
AU2006285097B2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
ATE514416T1 (de) Argatrobanformulierung mit einer säure als lösungsvermittler
BR112012031343A2 (pt) compostos de heteroarila contendo nitrogênio
WO2014066468A8 (en) Stable, low viscosity antibody formulation
BR112012024199A2 (pt) derivados de n-(imidazopirimidin-7-il)-heteroarilamida e seu uso como inibidores de pde10a
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
NI201200152A (es) Formulaciones de insulina de acción prolongada.
AR089211A1 (es) Fluido de fracturacion acuoso de baja viscosidad
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
BRPI0612957B8 (pt) composto, processos de preparação de compostos, composição farmacêutica e uso de um composto
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
BR112012017580A2 (pt) derivados de heteroarila contendo nitrogênio
ATE485261T1 (de) Salicylsäurederivate
BRPI0719277A2 (pt) Formulação fitossanitária concentrada, utilização da formulação e composição solvente compreendendo uma mistura de solventes
BRPI0909055A2 (pt) composto derivado de piridin-2-il, composição farmacêutica que o contém e uso desse composto.
UY29892A1 (es) Nuevos derivados de cromano, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones
CO6561809A2 (es) Composiciones antimicrobianas líquidas
BRPI0709772B8 (pt) sais de malato e polimorfos do ácido (3s,5s)-7-[3-amino-5-metil-piperidinil]-1-ciclopropil-1,4-diidro-8-metóxi-4-oxo-3-quinolinocarboxílico
BR112012033599A2 (pt) novos derivados de tetrahidroquinolina.
ATE511837T1 (de) Wässrige arzneimittelformulierung von 4-ä((4- carboxybutyl)-ä2-ä(4-phenethyl-benzyl)oxyü- phenethylüamino)methylübenzoesäure
GT201000184A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
BR112015029667A2 (pt) derivados de ureia macrocíclica como inibidores de tafia, sua preparação e seus usos como produtos farmacêuticos
EA200701741A1 (ru) Композиция, содержащая окаперидон
CR7118A (es) Nuevos derivados de acido sulfonico
CO6680615A2 (es) Formulaciones

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1948133

Country of ref document: EP